Literature DB >> 11438000

Rothmund-Thomson syndrome with myelodysplasia.

S Narayan1, C Fleming, A H Trainer, J A Craig.   

Abstract

Rothmund-Thomson syndrome (RTS) is a rare autosomal recessive disorder that is caused by a DNA repair defect. It is characterized mainly by skin, eye, and skeletal abnormalities. Cutaneous changes appear at between 3 and 6 months of age and include poikiloderma, photosensitivity, scaling, hyperkeratosis, and disturbance of hair growth. Other abnormalities include cataracts, congenital bone defects, soft tissue contractures, and osteogenesis imperfecta. Various malignancies have been reported in association with RTS, including osteosarcoma, fibrosarcoma, and nonmelanoma skin cancers. The myelodysplastic syndromes are a group of hematologic disorders defined by morphologic abnormalities of the three cell lines. The pathogenesis of myelodysplasia is a multistep process that begins with a somatic mutation in the pluripotential stem cell, which is irreversibly altered and acquires a survival advantage. Myelodysplasia in the young and RTS are both rare conditions. We report a patient with RTS and myelodysplasia. This is the second reported case of an association between these two conditions, which are both likely to be due to a common etiologic cause of nonrepair of stem cell DNA damage. Clinicians should be aware of the potential of this complication arising in patients with RTS.

Entities:  

Mesh:

Year:  2001        PMID: 11438000     DOI: 10.1046/j.1525-1470.2001.018003210.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  7 in total

1.  Identification of a novel C16orf57 mutation in Athabaskan patients with Poikiloderma with Neutropenia.

Authors:  Carol Clericuzio; Karine Harutyunyan; Weidong Jin; Robert P Erickson; Alan D Irvine; W H Irwin McLean; Yaran Wen; Rochelle Bagatell; Thomas A Griffin; Tor A Shwayder; Sharon E Plon; Lisa L Wang
Journal:  Am J Med Genet A       Date:  2010-12-22       Impact factor: 2.802

2.  Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm.

Authors:  Stephanie N Zimmer; Madeleine E Lemieux; Bijal P Karia; Claudia Day; Ting Zhou; Qing Zhou; Andrew L Kung; Uthra Suresh; Yidong Chen; Marsha C Kinney; Alexander J R Bishop; Vivienne I Rebel
Journal:  Exp Hematol       Date:  2011-12-20       Impact factor: 3.084

Review 3.  Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.

Authors:  Michael F Walsh; Vivian Y Chang; Wendy K Kohlmann; Hamish S Scott; Christopher Cunniff; Franck Bourdeaut; Jan J Molenaar; Christopher C Porter; John T Sandlund; Sharon E Plon; Lisa L Wang; Sharon A Savage
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

Review 4.  Rothmund-Thomson syndrome.

Authors:  Lidia Larizza; Gaia Roversi; Ludovica Volpi
Journal:  Orphanet J Rare Dis       Date:  2010-01-29       Impact factor: 4.123

Review 5.  Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?

Authors:  Ting Zhou; Paul Hasty; Christi A Walter; Alexander J R Bishop; Linda M Scott; Vivienne I Rebel
Journal:  Exp Hematol       Date:  2013-04-30       Impact factor: 3.084

6.  Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations.

Authors:  Elisa A Colombo; J Fernando Bazan; Gloria Negri; Cristina Gervasini; Nursel H Elcioglu; Deniz Yucelten; Ilknur Altunay; Umram Cetincelik; Anna Teti; Andrea Del Fattore; Matteo Luciani; Spencer K Sullivan; Albert C Yan; Ludovica Volpi; Lidia Larizza
Journal:  Orphanet J Rare Dis       Date:  2012-01-23       Impact factor: 4.123

Review 7.  Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.

Authors:  Ting Zhou; Peishuai Chen; Jian Gu; Alexander J R Bishop; Linda M Scott; Paul Hasty; Vivienne I Rebel
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.